CLAIM AMENDMENTS

Claims 1 through 19 (canceled).

Claim 20 (currently amended) Recombinant poxvirus comprising in the viral genome at least two expression cassettes, each comprising a cowpox ATI promoter according to SEQ ID NO:1, a polynucleotide sequence in which not more than 6 nucleotides are substituted, deleted, and/or inserted into SEQ ID NO:1, said sequence including nucleotides 25 through 29 of SEQ ID NO:1 and still active as an ATI promoter, or a polynucleotide comprising at least 10 nucleotides including nucleotides [[22]] 25 to 29 of SEQ ID NO: 1 and still active as an ATI promoter and a coding sequence, wherein the expression of the coding sequence is regulated by said promoter or said polynucleotides.

Claim 21 (previously presented) Recombinant poxvirus according to claim 20, wherein the Cowpox ATI promoter has the biological activity of being active as a Vaccinia virus late promoter.

Claim 22 (previously presented) Recombinant poxvirus according to claim 20, wherein the Cowpox ATI promoter is SEQ ID No: 1 or a polynucleotide which comprises at least 10 nucleotides including nucleotides 22 to 29 of SEQ ID No:1 and still active as an ATI promoter.

Claim 23 (previously presented) Recombinant poxvirus according to claim 20, wherein the Cowpox ATI promoters in each expression cassette, in the recombinant poxvirus are identical to one another.

Claim 24 (previously presented) Recombinant poxvirus according to claim 20, wherein at least two expression cassettes are inserted into the same insertion site in the poxvirus genome.

Claim 25 (previously presented) Recombinant poxvirus according to claim 20, wherein the Cowpox ATI promoter in at least one of the expression cassettes has the sequence of SEQ ID.: No. 1.

Claim 26 (previously presented) Recombinant poxvirus according to claim 20, wherein the Cowpox ATI promoter in the expression cassettes has the sequence of SEQ ID.: No. 1.

Claim 27 (previously presented) Recombinant poxvirus according to claim 20, wherein the poxvirus is selected from the group consisting of orthopoxviruses and avipoxviruses.

Claim 28 (previously presented) Recombinant poxvirus according to claim 27, wherein the orthopoxvirus is a vaccinia virus and wherein the avipoxvirus is selected from the group consisting of canarypoxvirus and fowlpoxvirus.

Claim 29 (previously presented) Recombinant poxvirus according to claim 28, wherein the vaccinia virus is modified vaccinia virus strain Ankara (MVA), in particular MVA-BN and MVA 575, deposited under numbers V00083008 and V00120707, respectively, at the European Collection of Animal Cell Cultures (ECACC).

Claim 30 (previously presented) Recombinant poxvirus according to claim 29, wherein at least one of the expression cassettes is inserted in a naturally occurring deletion site of the MVA genome with respect to the genome of the vaccinia virus strain Copenhagen.

Claim 31 (previously presented) Recombinant poxvirus according to claim 20, wherein at least one of the expression cassettes is inserted in an intergenic region of the poxvirus genome.

Claim 32 (previously presented) Recombinant poxvirus according to claim 20, wherein at least one of the coding sequences codes for at least one antigen, antigenic epitope, and/or a therapeutic compound.

Claim 33 (canceled)

Claim 34 (previously presented) Vaccine or pharmaceutical composition comprising a recombinant poxvirus according to claim 20.

Claim 35 (canceled)

Claim 36 (previously presented) Method for introducing coding sequences into target cells comprising the infection of the target cells with the virus according to claim 20.

Claim 37 (previously presented) Method for producing a peptide, protein and/or virus comprising:

a) infection of a host cell with the recombinant poxvirus according to claim 20,

b) cultivation of the infected host cell under suitable conditions, and

c) isolation and/or enrichment of the peptide and/or protein and/or viruses produced by said host cell.